STAT Plus: Pharmalittle: Gilead asks FDA to rescind orphan status for Covid-19 drug; Bristol delays MS drug launch due to coronavirus

Gilead Sciences asked the FDA to rescind orphan drug designation for an experimental medicine being tested to combat Covid-19 following intense criticism.

Click to view original post